Shanghai Heartcare Medical Technology Corp. Ltd. Class H
HHKEX:660953.30
HKD
+0.40
(+0.76%)
ISIN
CNE100004MN5
Return %
Stock
S&P 500
1Y
-4.48
14.20
3Y
105.39
81.12
5Y
-46.81
68.34
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Semi-annual Revenue
CNY
•
in mil. unless spec.Semi-annual Earnings Per Share
CNY
•
in mil. unless spec.Semi-annual Dividends Per Share
CNY
•
in mil. unless spec.Company Description
- CEO
- Guo Hui Wang
- Full Time Employees
- 368
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- Building 38 Shanghai SH China
- IPO Date
- Aug 20, 2021
- Website
- heartcare.com.cn
- Similar Companies
- Business
- Shanghai HeartCare Medical Technology Corporation Limited (6609.HK), founded in 2016 and headquartered in Shanghai's Lingang New Area, researches, develops, manufactures, and commercializes neuro-interventional medical devices primarily for stroke treatment and prevention in China and internationally. The company offers a comprehensive portfolio of NMPA-approved products including Captor thrombectomy stent retriever and aspiration catheters for acute ischemic stroke thrombectomy; intracranial balloon dilatation catheters, carotid artery stents, drug-eluting stents, and embolization protection systems for neurovascular stenosis; vascular reconstruction devices, embolic coils, and flow diverter devices for hemorrhagic stroke; left atrial appendage occluders for ischemic stroke prevention; and vascular access products such as distal access catheters, microcatheters, balloon guiding catheters, support catheters, neuro-interventional micro guidewires, vascular closure devices, and radial access catheter systems. Products are sold through an extensive network covering over 2,500 hospitals across all Chinese provinces except Macau, with R&D and production centers in Shanghai, Nanjing, and U.S. California facilities; the company holds 32 NMPA registrations, over 260 patents, and pursues overseas expansion with CE marks, FDA approvals, and registrations in 21 countries. In 2025, it launched a full suite of hemorrhagic stroke devices including NMPA-approved vascular reconstruction device, embolic coils, and flow diverter, driving first-half revenue growth of 44.4% to RMB185.5 million and gross margins to 68.2%; formed a strategic partnership with Hangzhou Matrix Medical Technology for Collseal vascular closure device promotion; commenced an equity buyback program authorized in May 2025; and advanced R&D on self-expanding drug stents, carotid stents, and interventional brain-computer interfaces while securing additional CE and FDA certifications for key thrombectomy and access devices.